{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T13:42:00Z","timestamp":1759412520294},"reference-count":49,"publisher":"Elsevier BV","issue":"24","license":[{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Research on Emerging and Re-emerging Infectious Diseases"},{"name":"Health and Labour Sciences Research Grants from the Ministry of Health, Labour and Welfare, Japan"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1016\/j.vaccine.2017.04.046","type":"journal-article","created":{"date-parts":[[2017,5,4]],"date-time":"2017-05-04T18:01:21Z","timestamp":1493920881000},"page":"3264-3271","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Cost-effectiveness of varicella vaccine against herpes zoster and post-herpetic neuralgia for elderly in Japan"],"prefix":"10.1016","volume":"35","author":[{"given":"Shu-ling","family":"Hoshi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahide","family":"Kondo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ichiro","family":"Okubo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2017.04.046_b0005","series-title":"Principles and practice of infectious diseases","first-page":"1731","article-title":"Varicella zoster virus","author":"Whitley","year":"2015"},{"issue":"1","key":"10.1016\/j.vaccine.2017.04.046_b0010","first-page":"9","article-title":"The nature of herpes zoster: a long-term study and a new hypothesis","volume":"58","author":"Hope-Simpson","year":"1965","journal-title":"Proc R Soc Med"},{"issue":"25","key":"10.1016\/j.vaccine.2017.04.046_b0015","first-page":"265","article-title":"WHO position paper position paper, June 2014","volume":"89","author":"Varicella and Herpes Zoster vaccines","year":"2014","journal-title":"Wkly Epidemiol Rec"},{"issue":"12","key":"10.1016\/j.vaccine.2017.04.046_b0020","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1002\/jmv.21599","article-title":"Society of the Miyazaki Prefecture Dermatologists. Epidemiology of herpes zoster and its relationship to varicella in Japan: A 10-year survey of 48,388 herpes zoster cases in Miyazaki prefecture","volume":"81","author":"Toyama","year":"2009","journal-title":"J Med Virol"},{"issue":"10","key":"10.1016\/j.vaccine.2017.04.046_b0025","doi-asserted-by":"crossref","first-page":"617","DOI":"10.2188\/jea.JE20140210","article-title":"Incidences of herpes zoster and postherpetic neuralgia in Japanese adults aged 50 years and older from a community-based prospective cohort study: the SHEZ study","volume":"25","author":"Takao","year":"2015","journal-title":"J Epidemiol"},{"issue":"10","key":"10.1016\/j.vaccine.2017.04.046_b0030","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1111\/1346-8138.13334","article-title":"Relationship between prior knowledge about herpes zoster and the period from onset of the eruption to consultation in patients with herpes zoster","volume":"43","author":"Miyachi","year":"2016","journal-title":"J Dermatol"},{"key":"10.1016\/j.vaccine.2017.04.046_b0035","unstructured":"Merck & Co., Inc. ZOSTAVAX\u00ae (Zoster Vaccine Live) [HIGHLIGHTS OF PRESCRIBING INFORMATION]. Available from: <http:\/\/www.merck.com\/product\/usa\/pi_circulars\/z\/zostavax\/zostavax_pi2.pdf>."},{"issue":"15","key":"10.1016\/j.vaccine.2017.04.046_b0040","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1016\/j.vaccine.2014.01.058","article-title":"Cost-effectiveness of vaccination against herpes zoster and postherpetic neuralgia: a critical review","volume":"32","author":"Kawai","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.04.046_b0045","doi-asserted-by":"crossref","first-page":"161","DOI":"10.11150\/kansenshogakuzasshi.85.161","article-title":"Varicella vaccine potency and stability during transport and delivery","volume":"85","author":"Kamiya","year":"2011","journal-title":"Kansenshogaku Zasshi"},{"key":"10.1016\/j.vaccine.2017.04.046_b0050","unstructured":"Record of proceedings of the committee of Immunisation and Vaccine, Health Science Council, Ministry of Health, Welfare and Labour of Japan; 2016. June 22. Available from: <http:\/\/www.mhlw.go.jp\/stf\/shingi2\/0000130809.html> [Japanese]."},{"key":"10.1016\/j.vaccine.2017.04.046_b0055","unstructured":"TreeAge Pro 2015, R1.0. TreeAge Software, Williamstown, MA; software available at <https:\/\/www.treeage.com>."},{"key":"10.1016\/j.vaccine.2017.04.046_b0060","unstructured":"Ministry of Internal Affairs and Communications. Population estimates of Japan. Statistics Bureau, Tokyo; 2002."},{"key":"10.1016\/j.vaccine.2017.04.046_b0065","unstructured":"Ministry of Health, Labour and Welfare. [Teiki no yobou seshu jishisyshu (Uptake rates of routine vaccinations), 1995\u20132015]. Ministry of Health, Labour and Welfare, Tokyo. Available from: <http:\/\/www.mhlw.go.jp\/topics\/bcg\/other\/5.html> [Japanese]."},{"issue":"23\u201324","key":"10.1016\/j.vaccine.2017.04.046_b0070","doi-asserted-by":"crossref","first-page":"3076","DOI":"10.1016\/S0264-410X(01)00044-5","article-title":"The epidemiology of herpes zoster and potential cost-effectiveness of vaccination in England and Wales","volume":"19","author":"Edmunds","year":"2001","journal-title":"Vaccine"},{"issue":"49","key":"10.1016\/j.vaccine.2017.04.046_b0075","doi-asserted-by":"crossref","first-page":"8326","DOI":"10.1016\/j.vaccine.2007.09.066","article-title":"Evaluation of the cost-effectiveness in the United States of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults","volume":"25","author":"Pellissier","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.04.046_b0080","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1478-7547-8-7","article-title":"A health economic model for evaluating a vaccine for the prevention of herpes zoster and post-herpetic neuralgia in the UK","volume":"8","author":"Moore","year":"2010","journal-title":"Cost Eff Resour Alloc"},{"key":"10.1016\/j.vaccine.2017.04.046_b0085","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1186\/1472-6963-10-237","article-title":"Assessing the potential effects and cost-effectiveness of programmatic herpes zoster vaccination of elderly in the Netherlands","volume":"10","author":"van Lier","year":"2010","journal-title":"BMC Health Serv Res"},{"issue":"3","key":"10.1016\/j.vaccine.2017.04.046_b0090","doi-asserted-by":"crossref","first-page":"537","DOI":"10.3111\/13696998.2010.502854","article-title":"Health economic evaluation of a vaccine for the prevention of herpes zoster (shingles) and post-herpetic neuralgia in adults in Belgium","volume":"13","author":"Annemans","year":"2010","journal-title":"J Med Econ"},{"issue":"7","key":"10.1016\/j.vaccine.2017.04.046_b0095","doi-asserted-by":"crossref","first-page":"749","DOI":"10.4161\/hv.7.7.15573","article-title":"Economic evaluation of a vaccine for the prevention of herpes zoster and post-herpetic neuralgia in older adults in Switzerland","volume":"7","author":"Szucs","year":"2011","journal-title":"Hum Vaccin"},{"issue":"3","key":"10.1016\/j.vaccine.2017.04.046_b0100","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.vaccine.2011.10.036","article-title":"Cost-effectiveness of vaccination against herpes zoster in adults aged over 60 years in Belgium","volume":"30","author":"Bilcke","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.04.046_b0105","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1186\/1472-6963-13-359","article-title":"Health economic evaluation of vaccination strategies for the prevention of herpes zoster and postherpetic neuralgia in Germany","volume":"13","author":"Ultsch","year":"2013","journal-title":"BMC Health Serv Res"},{"issue":"4","key":"10.1016\/j.vaccine.2017.04.046_b0110","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1080\/21645515.2015.1011561","article-title":"Cost-effectiveness analysis of a vaccination program for the prevention of herpes zoster and post-herpetic neuralgia in adults aged 50 and over in Germany","volume":"11","author":"Pr\u00e9aud","year":"2015","journal-title":"Hum Vaccin Immunother"},{"issue":"7","key":"10.1016\/j.vaccine.2017.04.046_b0115","doi-asserted-by":"crossref","first-page":"489","DOI":"10.7326\/M15-0093","article-title":"Cost-effectiveness of herpes zoster vaccine for persons aged 50 years","volume":"163","author":"Le","year":"2015","journal-title":"Ann Intern Med"},{"issue":"4","key":"10.1016\/j.vaccine.2017.04.046_b0120","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1017\/S0266462316000337","article-title":"Cost-effectiveness analysis of herpes zoster vaccination in Italian elderly persons","volume":"32","author":"Coretti","year":"2016","journal-title":"Int J Technol Assess Health Care"},{"issue":"6","key":"10.1016\/j.vaccine.2017.04.046_b0125","doi-asserted-by":"crossref","first-page":"576","DOI":"10.3111\/13696998.2016.1146726","article-title":"The use of Zostavax in Spain: the economic case for vaccination of individuals aged 50 years and older","volume":"19","author":"Lopez-Belmonte","year":"2016","journal-title":"J Med Econ"},{"issue":"9","key":"10.1016\/j.vaccine.2017.04.046_b0130","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.1080\/21645515.2016.1184801","article-title":"Cost-effectiveness of a herpes zoster vaccination program among the French elderly people","volume":"12","author":"Belchior","year":"2016","journal-title":"Hum Vaccin Immunother"},{"issue":"2","key":"10.1016\/j.vaccine.2017.04.046_b0135","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s11606-016-3844-6","article-title":"Determining the optimal vaccination schedule for herpes zoster: a cost-effectiveness analysis","volume":"32","author":"Le","year":"2017","journal-title":"J Gen Intern Med."},{"issue":"3","key":"10.1016\/j.vaccine.2017.04.046_b0140","doi-asserted-by":"crossref","first-page":"238","DOI":"10.4161\/hv.4.3.5686","article-title":"The potential cost-effectiveness of vaccination against herpes zoster and post-herpetic neuralgia","volume":"4","author":"Brisson","year":"2008","journal-title":"Hum Vaccin"},{"issue":"5","key":"10.1016\/j.vaccine.2017.04.046_b0145","doi-asserted-by":"crossref","first-page":"317","DOI":"10.7326\/0003-4819-145-5-200609050-00004","article-title":"Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults","volume":"145","author":"Hornberger","year":"2006","journal-title":"Ann Intern Med"},{"issue":"10","key":"10.1016\/j.vaccine.2017.04.046_b0150","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1086\/514342","article-title":"Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults","volume":"44","author":"Rothberg","year":"2007","journal-title":"Clin Infect Dis"},{"issue":"3","key":"10.1016\/j.vaccine.2017.04.046_b0155","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1586\/erp.13.19","article-title":"Vaccination against herpes zoster and postherpetic neuralgia in France: a cost-effectiveness analysis","volume":"13","author":"Bresse","year":"2013","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"12","key":"10.1016\/j.vaccine.2017.04.046_b0160","doi-asserted-by":"crossref","first-page":"991","DOI":"10.2165\/11314010-000000000-00000","article-title":"Cost effectiveness of herpes zoster vaccine in Canada","volume":"27","author":"Najafzadeh","year":"2009","journal-title":"Pharmacoeconomics"},{"issue":"9","key":"10.1016\/j.vaccine.2017.04.046_b0165","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1016\/j.vaccine.2008.12.024","article-title":"Estimating the cost-effectiveness of vaccination against herpes zoster in England and Wales","volume":"27","author":"van Hoek","year":"2009","journal-title":"Vaccine"},{"issue":"9","key":"10.1016\/j.vaccine.2017.04.046_b0170","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1016\/j.vaccine.2012.12.067","article-title":"Cost-effectiveness of vaccination of the elderly against herpes zoster in The Netherlands","volume":"31","author":"de Boer","year":"2013","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.vaccine.2017.04.046_b0175","first-page":"CD008858","article-title":"Vaccines for preventing herpes zoster in older adults","volume":"3","author":"Gagliardi","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.vaccine.2017.04.046_b0180","unstructured":"Ministry of Health, Labour and Welfare. Vital statistics of Japan 2015. Health and Welfare Statistics Association, Tokyo. Available from: <http:\/\/www.e-stat.go.jp\/SG1\/estat\/List.do?lid=000001158448> [Japanese]."},{"issue":"22","key":"10.1016\/j.vaccine.2017.04.046_b0185","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1056\/NEJMoa051016","article-title":"Shingles Prevention Study group. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults","volume":"352","author":"Oxman","year":"2005","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.vaccine.2017.04.046_b0190","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1093\/cid\/cis638","article-title":"Shingles Prevention Study Group. Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy","volume":"55","author":"Schmader","year":"2012","journal-title":"Clin Infect Dis"},{"issue":"6","key":"10.1016\/j.vaccine.2017.04.046_b0195","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1093\/cid\/ciu918","article-title":"Shingles Prevention Study Group. Long-term persistence of zoster vaccine efficacy","volume":"60","author":"Morrison","year":"2015","journal-title":"Clin Infect Dis"},{"issue":"12","key":"10.1016\/j.vaccine.2017.04.046_b0200","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1016\/j.vaccine.2014.10.039","article-title":"Modeling the durability of ZOSTAVAX\u00ae vaccine efficacy in people \u226560 years of age","volume":"33","author":"Li","year":"2015","journal-title":"Vaccine"},{"issue":"16","key":"10.1016\/j.vaccine.2017.04.046_b0205","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1503\/cmaj.091711","article-title":"The impact of herpes zoster and postherpetic neuralgia on health-related quality of life: a prospective study","volume":"182","author":"Drolet","year":"2010","journal-title":"CMAJ"},{"issue":"12","key":"10.1016\/j.vaccine.2017.04.046_b0210","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1111\/jdv.12379","article-title":"One-year follow-up of zoster-associated pain in 764 immunocompetent patients with acute herpes zoster treated with famciclovir (FAMILIAR study)","volume":"28","author":"Imafuku","year":"2014","journal-title":"Eur Acad Dermatol Venereol"},{"issue":"1","key":"10.1016\/j.vaccine.2017.04.046_b0215","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3820\/jjpe.16.1","article-title":"Cost-effectiveness analysis of pregabalin for treatment of peripheral neuropathic pain","volume":"16","author":"Ikeda","year":"2011","journal-title":"Jpn J Pharmacoepidemiol"},{"key":"10.1016\/j.vaccine.2017.04.046_b0220","series-title":"Methods for the economic evaluation of health care programmes","author":"Drummond","year":"2015"},{"key":"10.1016\/j.vaccine.2017.04.046_b0225","unstructured":"Record of proceedings of the committee of cost-effectiveness, Central Social Insurance Medical Council, Ministry of Health, Welfare and Labour of Japan. 2017. March 15. Available from: <http:\/\/www.mhlw.go.jp\/stf\/shingi\/shingi-chuo.html?tid=128159> [Japanese]."},{"issue":"4","key":"10.1016\/j.vaccine.2017.04.046_b0230","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1002\/hec.1481","article-title":"International survey on willingness-to-pay (WTP) for one additional QALY gained: what is the threshold of cost effectiveness?","volume":"19","author":"Shiroiwa","year":"2010","journal-title":"Health Econ"},{"key":"10.1016\/j.vaccine.2017.04.046_b0235","unstructured":"Institute of Medicine (US) Committee to Study Priorities for Vaccine Development; Stratton KR, Durch JS, Lawrence RS, editors. Vaccines for the 21st century: a tool for decisionmaking. Washington (DC): National Academies Press (US); 2000."},{"key":"10.1016\/j.vaccine.2017.04.046_b0240","unstructured":"World Health Organization. WHO guide for standardization of economic evaluations of immunization programmes. Geneva, Switzerland: WHO Document Production Services; 2008."},{"issue":"6","key":"10.1016\/j.vaccine.2017.04.046_b0245","doi-asserted-by":"crossref","first-page":"e66485","DOI":"10.1371\/journal.pone.0066485","article-title":"Herpes zoster risk reduction through exposure to chickenpox patients: a systematic multidisciplinary review","volume":"8","author":"Ogunjimi","year":"2013","journal-title":"PLoS ONE"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X17305376?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X17305376?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,6,25]],"date-time":"2018-06-25T08:39:31Z","timestamp":1529915971000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X17305376"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":49,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2017,5]]}},"alternative-id":["S0264410X17305376"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.04.046","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost-effectiveness of varicella vaccine against herpes zoster and post-herpetic neuralgia for elderly in Japan","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.04.046","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}